Recently, the safety of the combination of trabectedin chemotherapy and olaparib PARP inhibitor in second‐line or further‐line has been shown in patients with advanced sarcomas (Grignani et al., 2018), with a promising 18% partial response in patients with STS. This evidence concerns the gene PARP1 and telomere syndrome.